The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Health-related quality of life (HRQoL) has been shown to be a prognostic factor for cancer survival in randomized clinical trials and observational “real-world” cohort studies; however, it remains unclear which HRQoL domains are the best prognosticators. The primary aims of this population-based, observational study were to (a) investigate the association between the novel European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (QLQ-C30) summary score and all-cause mortality, adjusting for the more traditional sociodemographic and clinical prognostic factors; and (b) compare the prognostic value of the QLQ-C30 summary score with the global quality of life (QoL) and physical functioning scales of the QLQ-C30. Materials and Methods: Between 2008 and 2015, patients with cancer (12 tumor types) were invited to participate in PROFILES disease-specific registry studies (response rate, 69%). In this secondary analysis of 6,895 patients, multivariate Cox proportional hazard regression models were used to investigate the association between the QLQ-C30 scores and all-cause mortality. Results: In the overall Cox regression model including sociodemographic and clinical variables, the QLQ-C30 summary score was associated significantly with all-cause mortality (hazard ratio [HR], 0.77; 99% confidence interval [CI], 0.71–0.82). In stratified analyses, significant associations between the summary score and all-cause mortality were observed for colon, rectal, and prostate cancer, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The QLQ-C30 summary score had a stronger association with all-cause mortality than the global QoL scale (HR, 0.82; 99% CI, 0.77–0.86) or the physical functioning scale (HR, 0.81; 95% CI, 0.77–0.85). Conclusion: In a real-world setting, the QLQ-C30 summary score has a strong prognostic value for overall survival for a number of populations of patients with cancer above and beyond that provided by clinical and sociodemographic variables. The QLQ-C30 summary score appears to have more prognostic value than the global QoL, physical functioning, or any other scale within the QLQ-C30.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationWilson, I. B. (1995) · JAMA · doi:10.1001/jama.1995.03520250075037 · Cited by 3,027
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0830 · Cited by 2,593
What is self-rated health and why does it predict mortality? Towards a unified conceptual model
Jylhä, M. (2009) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.05.013 · Cited by 2,578
Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017) · JAMA · doi:10.1001/jama.2017.7156 · Cited by 2,302
Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.078 · Cited by 1,382
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D. V., & Aaronson, N. K. (2002) · JAMA · doi:10.1001/jama.288.23.3027 · Cited by 1,011
Self-citationDi Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9334 · Cited by 497
Research works printed but not linked: 24
- Basch, 2015, Methods for developing patient-reported outcome-based performance measures (PRO-PMs), Value Health, 18, 493, 10.1016/j.jval.2015.02.018 · DOI
- Acquadro, 2003, Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001, Value Health, 6, 522, 10.1046/j.1524-4733.2003.65309.x · DOI · Paper page
- Kluetz, 2016, Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms, Clin Cancer Res, 22, 1553, 10.1158/1078-0432.CCR-15-2035 · DOI · Paper page
- Quinten, 2014, A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites, Cancer, 120, 302, 10.1002/cncr.28382 · DOI · Paper page
- Quinten, 2009, Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials, Lancet Oncol, 10, 865, 10.1016/S1470-2045(09)70200-1 · DOI · Paper page
- Gotay, 2008, The prognostic significance of patient-reported outcomes in cancer clinical trials, J Clin Oncol, 26, 1355, 10.1200/JCO.2007.13.3439 · DOI · Paper page
- Ediebah, 2018, Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials, Cancer, 124, 3409, 10.1002/cncr.31556 · doi:10.1002/cncr.31556
- Meyer, 2015, Big data infrastructure for cancer outcomes research: Implications for the practicing oncologist, J Oncol Pract, 11, 207, 10.1200/JOP.2015.004432 · doi:10.1200/jop.2015.004432
- Montazeri, 2009, Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008, Health Qual Life Outcomes, 7, 102, 10.1186/1477-7525-7-102 · DOI · Paper page
- Efficace, 2004, Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer, Eur J Cancer, 40, 1021, 10.1016/j.ejca.2004.01.014 · DOI · Paper page
- Groenvold, 2016, EORTC Quality of Life Group. Focusing on core patient-reported outcomes in cancer clinical trials-letter, Clin Cancer Res, 22, 5617, 10.1158/1078-0432.CCR-16-1529 · doi:10.1158/1078-0432.ccr-16-1529
- Giesinger, 2016, Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust, J Clin Epidemiol, 69, 79, 10.1016/j.jclinepi.2015.08.007 · DOI · Paper page
- Pagano, 2006, Modeling quality of life in cancer patients as a unidimensional construct, Hawaii Med J, 65, 76
- Galvin, 2018, Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly, J Geriatr Oncol, 9, 6, 10.1016/j.jgo.2017.07.007 · DOI
- Poll-Franse, 2011, The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts, Eur J Cancer, 47, 2188, 10.1016/j.ejca.2011.04.034 · DOI · Paper page
- Fritz, 2000, International Classification of Diseases for Oncology
- Sobin, 1997, Union Internationale Contre le Cancer and the American Joint Committee on Cancer, Cancer, 80, 1803, 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9 · DOI · Paper page
- Cocks, 2011, Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, J Clin Oncol, 29, 89, 10.1200/JCO.2010.28.0107 · DOI · Paper page
- Gundy, 2012, Comparing higher order models for the EORTC QLQ-C30, Qual Life Res, 21, 1607, 10.1007/s11136-011-0082-6 · DOI
- Rooij, 2018, Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: The population-based PROFILES registry, Qual Life Res, 27, 3313, 10.1007/s11136-018-1979-0 · DOI
- Antoni, 2013, Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer, Brain Behav Immun, 30, S88, 10.1016/j.bbi.2012.05.009 · DOI · Paper page
- Valderas, 2008, The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature, Qual Life Res, 17, 179, 10.1007/s11136-007-9295-0 · DOI · Paper page
- Chen, 2013, A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting, BMC Health Serv Res, 13, 211, 10.1186/1472-6963-13-211 · DOI · Paper page
- Corsini, 2017, Cancer survivorship monitoring systems for the collection of patient-reported outcomes: A systematic narrative review of international approaches, J Cancer Surviv, 11, 486, 10.1007/s11764-017-0607-2 · DOI
Cited by
Di Meglio, A., Havas, J., Gbenou, A. S., Martin, E., El-Mouhebb, M., Pistilli, B., Menvielle, G., Dumas, A., Everhard, S., Martin, A.-L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00277 · Cited by 76
“Model selection metrics are presented in the Data Supplement.”
BackgroundMethodInfluentialVaz-Luis, I., Di Meglio, A., Havas, J., El-Mouhebb, M., Lapidari, P., Presti, D., Soldato, D., Pistilli, B., Dumas, A., Menvielle, G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01958 · Cited by 65
“Both instruments provide a four-point Likert scale response for each item: not at all, a little, quite a bit, and very much.(17-19) All items are converted to a 0-100 scale using a standard scoring algorithm, where higher scores reflect greater fatigue severity.”
MethodCurrow, D. C., Maddocks, M., Cella, D., & Muscaritoli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113471 · Cited by 27
Lee, M. K., Mitchell, S. A., Basch, E., Mazza, G. L., Langlais, B. T., Thanarajasingam, G., Ginos, B. F., Rogak, L., Meek, E. A., Jansen, J., et al. (2025) · Quality of Life Research · doi:10.1007/s11136-024-03819-5 · Cited by 8
Metadata
- Authors
- Husson, O., de Rooij, B. H., Kieffer, J., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-31
- Volume
- 25
- Issue
- 4
- Pages
- e722-e732
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2979404832
- Cited by
- 245
- References
- 10
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry. https://app.cochat.ai/papers/10.1634/theoncologist.2019-0348
- The paper
- Husson, O., de Rooij, B. H., Kieffer, J., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2020). The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry. The Oncologist. https://doi.org/10.1634/theoncologist.2019-0348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.